Optibrium Enhances Compound Design Strategies in Major Upgrade to StarDrop Software

• New features include reaction-based library enumeration for novel molecule generation and optimisation • AI-integrated with seamless interface to Optibrium’s Artificial Intelligence platform, Cerella, to extract greater value from drug discovery data

European Medicines Agency Selects Panalgo for Real-World Data Analytics

The EMA will use Panalgo’s Instant Health Data (IHD) platform to rapidly answer questions around drug safety and efficacy and better understand real-world medication use.

BOC Sciences comprehensively deploys liposomal drug delivery research to seek industry-wide cooperation

Panthera began dosing volunteers in AstraZeneca’s phase III of its long-acting antibody combination AZD7442 for the prevention of COVID-19 at its sites in Preston, North Manchester and North London

Panthera’s clinical trial sites are helping to evaluate an alternative AstraZeneca vaccine for people who are unable to have the currently approved Covid-19 vaccines. The treatment is aimed at helping those people with a compromised immune system, who cannot be vaccinated, vaccine hesitant and those who are unlikely to respond to a vaccination.

Enveda Biosciences Systematically Harnesses Untapped Potential of Nature’s Chemistry to Develop Next-Gen Therapeutics

ComputaBio Has Launched Molecular Dynamics Simulation Services for Drug R&D Projects

ComputaBio, a US supplier of professional computational biology services, has launched molecular dynamics simulation services for industrial and academic customers to expedite the process of drug design.

Octapharma Selects Model N Revenue Cloud for Life Sciences

BOC RNA and Dr. Shiyue Fang Announced Plans to Cooperate Closely in Sensitive DNA/RNA Synthesis

Alfa Chemistry Supplies Varieties of Dyes for Industrial Use

AMZELL to initiate FDA-approved Phase 3 trial of innovative injectable treatment for infantile epileptic disease

Specialist development pharmaceutical company AMZELL B.V has concluded discussions with the FDA ahead of initiating a Phase 3 trial of its new treatment for infantile epileptic disease, AMZ002.

Matexcel Provides a Wide Selection of Antimicrobial Material Products

Real-time logistics monitoring from Roambee proven to address COVID-19 vaccine distribution challenges

Roambee’s technology solution for real-time logistics visibility has been proven to overcome many of the challenges of global COVID-19 vaccine distribution.

TRIBAL WORLDWIDE TO LAUNCH NEW TOTAL HEALTH EXPERIENCE AGENCY

Tribal Health will bridge the gap between brand promise and brand experience in healthcare for clients GSK, Gilead and Medela.

Wasdell Group strengthens PPFL business with ISO 13485 for medical devices

TRU-ZERO™ LIQUID STABLE BILIRUBIN STANDARD NOW AVAILABLE FROM VERICHEM LABORATORIES

VERICHEM LABORATORIES now offers the TRU-ZERO™ BILIRUBIN STANDARD – a liquid stable, protein based, standard material intended for the AMR and calibration verification of Total and Direct bilirubin assays with a number of chemistry testing systems.

Watson-Marlow pump equips tablet-coating turbine at Bailly Creat

Bailly Creat recently standardised on 530S peristaltic pumps from Watson-Marlow Fluid Technology Group for its lamination process.

Dotmatics appoints Matt Burnett as Chief Technology Officer

AVIA Releases Free Resource to Accelerate Digital Health Legal Contracting

CluePoints Opens New AsiaPac Office in Tokyo

CluePoints, the premier provider of Central Statistical Monitoring, Risk-Based Quality Management and Data Quality Oversight Software for clinical trials, today announced further expansion in Japan with the opening of a new office in Tokyo. Dedicated to serving their Japanese clients, the new office builds on CluePoints’ presence in the region, as demand for modern analytical software and services enabling proactive and exhaustive identification of clinical study quality issues continues to grow. The new location, along with a team located in Osaka, will strengthen CluePoints’ growing reputation within Japan and bring it closer to its Asia-Pacific region customers.

NanoSyrinx strengthens board with appointment of Dr Jane Dancer as Non-Executive Director

NanoSyrinx announces the appointment of Dr Jane Dancer to its Board as Non-Executive Director. Dr Dancer has over 30 years’ experience in business development across biotech, pharma and agrochemicals and her experience will help to drive NanoSyrinx’s ongoing fundraising activities and ambitious growth plans.